-
Stephan Moll, MD writes (last updated: Sept 9th, 2020)… Background: Hospitalized patients with COVID-19 are at increased risk for thrombosis – DVT, PE, and may be pulmonary micro-vascular thrombosis that possibly contributes to respiratory failure; arterial events appear to occur less commonly. Scientific/clinical data on prevalence of thrombosis, best prevention, and optimal therapy are limited.
-
Many people think of blood clots as a problem occurring in elderly people, but not in young and apparently healthy individuals. While it is true that clots occur more commonly in the elderly and in non-athletic overweight individuals, they can, nevertheless, happen in young, normal weight, and athletic people.
-
Testosterone Replacement Therapy Replacement therapy with low doses of testosterone does not adversely affect blood coagulation status [ref 1] and does not appear to increase the risk of venous or arterial thrombosis. Thrombosis is not listed as a potential side effect in the commly used drug compendium (Micromedex). Furthermore, the 2006 “Clinical Practice Guideline” from the
-
Testosterone Replacement Therapy Replacement therapy with low doses of testosterone does not adversely affect blood coagulation status [ref 1] and does not appear to increase the risk of venous or arterial blood clots. Thrombosis is not listed as a potential side effect in a commly used drug compendium (Micromedex). Furthermore, the 2006 “Clinical Practice Guideline”
-
What is HHT? HHT (Hereditary Hemorrhagic Teleangiectasia), called Osler-Weber-Rendu syndrome, is an inherited disorder in which small blood vessels develop abnormally [ref 1]. It is estimated that 30,000 to 60,000 people (1 out 5,000 to 10,000) in the United States are affected. Individuals with HHT develop telengiectasias in the skin (usually in the fingers and hands) and
-
What is HHT? HHT (Hereditary Hemorrhagic Teleangiectasia) is an inherited disorder in which small blood vessels develop abnormally [ref 1]. It is also called Osler-Weber-Rendu syndrome. It is estimated that 30,000 to 60,000 people (1 out every 5,000 to 10,000) in the United States have it. Individuals with HHT develop small abnormal blood vessels (teleangiectasias)
-
If you as a health care professional are involved in the management of patients with acute (proximal) DVT, please consider giving the patient (who has leg symptoms ≤ 14 days) an opportunity to be enrolled in the national ATTRACT trial (information on the trial is here). This NIH-funded, multi-center trial investigates whether catheter-directed thrombectomy (±
-
If you or somebody you know has been diagnosed in the last 14 days with a new DVT of the leg (thigh or pelvic veins), I would encourage you to consider participation in the ATTRACT trial – a solid, clinically useful study (NIH funded) that investigates how to minimize the long-term complications after a blood clot –
-
A discussion of PFO and paradoxical embolism, written for patients, is available on the Clot Connect Patient blog- connect here. The health care professional can refer his/her patient to the information on PFO in that blog . The blog also contains images suitable for patients to understand the etiology of paradoxical embolism:
-
Anatomy Some people have a “hole in the heart”, called a “patent foramen ovale” (PFO). This is a connection between the right and the left chamber (atrium) of the heart. We are all born with it – the unborn needs this connection for proper blood circulation. In most people the hole closes in the first
-
A detailed discussion of Heparin-Induced Thrombocytopenia (HIT) written for patients is available on the Clot Connect Patient blog- connect here. We hope that the health care professional will consider this document to be suitable as an information handout to his/her patients with HIT. The discussion also contains 2 resources for use by the health care provider:
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 